ATE352317T1 - Therapeutische behandlung von eosinophilie durch verwendung von chymase-inhibitoren als aktiven bestandteilen - Google Patents

Therapeutische behandlung von eosinophilie durch verwendung von chymase-inhibitoren als aktiven bestandteilen

Info

Publication number
ATE352317T1
ATE352317T1 AT01906225T AT01906225T ATE352317T1 AT E352317 T1 ATE352317 T1 AT E352317T1 AT 01906225 T AT01906225 T AT 01906225T AT 01906225 T AT01906225 T AT 01906225T AT E352317 T1 ATE352317 T1 AT E352317T1
Authority
AT
Austria
Prior art keywords
eosinophily
active ingredients
therapeutic treatment
chymase inhibitors
treatment
Prior art date
Application number
AT01906225T
Other languages
English (en)
Inventor
Harukazu Fukami
Naohiro Watanabe
Original Assignee
Daiichi Asubio Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Asubio Pharma Co Ltd filed Critical Daiichi Asubio Pharma Co Ltd
Application granted granted Critical
Publication of ATE352317T1 publication Critical patent/ATE352317T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C07D239/96—Two oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT01906225T 2000-02-22 2001-02-22 Therapeutische behandlung von eosinophilie durch verwendung von chymase-inhibitoren als aktiven bestandteilen ATE352317T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2000050487 2000-02-22

Publications (1)

Publication Number Publication Date
ATE352317T1 true ATE352317T1 (de) 2007-02-15

Family

ID=18572266

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01906225T ATE352317T1 (de) 2000-02-22 2001-02-22 Therapeutische behandlung von eosinophilie durch verwendung von chymase-inhibitoren als aktiven bestandteilen

Country Status (11)

Country Link
US (1) US6677344B2 (de)
EP (1) EP1174151B1 (de)
KR (1) KR20010109526A (de)
CN (1) CN1245978C (de)
AT (1) ATE352317T1 (de)
AU (1) AU3413501A (de)
CA (1) CA2365606A1 (de)
DE (1) DE60126199T2 (de)
ES (1) ES2275652T3 (de)
HU (1) HUP0201287A3 (de)
WO (1) WO2001062293A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3413601A (en) 2000-02-22 2001-09-03 Daiichi Asubio Pharma Co., Ltd. Preventive or therapeutic drugs for dermatitises containing chymase inhibitors as the active ingredient
AU3413401A (en) 2000-02-22 2001-09-03 Daiichi Asubio Pharma Co., Ltd. Preventive or therapeutic drugs for fibrosis containing chymase inhibitors as the active ingredient
AU2005310490B2 (en) 2004-12-02 2012-01-19 Daiichi Sankyo Company, Limited 7-membered ring compound, process for producing the same, and medicinal use thereof
JP5117382B2 (ja) 2006-05-31 2013-01-16 第一三共株式会社 ７員環化合物の製造方法
DE102009043745A1 (de) 2009-09-30 2011-04-07 Carl Zeiss Microlmaging Gmbh Spektraldetektor mit variabler Filterung durch räumliche Farbtrennung und Laser-Scanning- Mikroskop
PH12012501228A1 (en) 2009-12-25 2012-11-05 Daiichi Sankyo Co Ltd Seven-membered ring compound and pharmaceutical use therefor
US11840543B2 (en) 2017-05-24 2023-12-12 The University Of Queensland Compounds and uses

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6351335A (ja) * 1986-08-20 1988-03-04 Fuji Oil Co Ltd 肥満細胞脱顆粒抑制剤
US5199279A (en) 1991-08-13 1993-04-06 Reynolds Martin M Drum contact freezer system and method
JPH05294930A (ja) * 1992-04-21 1993-11-09 Yoshitomi Pharmaceut Ind Ltd スチリル化合物
CA2137832C (en) 1992-06-12 2000-09-26 Dennis J. Hoover Inhibitors of angiotensin i chymase(s) including human heart chymase
CN1050355C (zh) 1993-05-12 2000-03-15 纳幕尔杜邦公司 稠合双环嘧啶酮类化合物、含有它们的杀真菌组合物及其应用
WO1996004248A1 (en) 1994-07-29 1996-02-15 Suntory Limited Imidazolidine derivative and use thereof
CA2163399A1 (en) 1994-11-24 1996-05-25 Katsuhiro Kawano Triazine derivative, chymase activity inhibitor and nitric oxide production inhibitor
US5948785A (en) 1995-04-27 1999-09-07 The Green Cross Corporation Heterocyclic amide compounds and pharmaceutical use of the same
US5596111A (en) 1995-06-05 1997-01-21 North Dakota State University Method for preparation of carboxylic acids
WO1997011941A1 (fr) * 1995-09-28 1997-04-03 Suntory Limited Derives de la quinazoline et leurs emplois
JP4199309B2 (ja) * 1996-09-06 2008-12-17 日本化薬株式会社 新規アセトアミド誘導体およびプロテアーゼ阻害
JPH1087493A (ja) * 1996-09-18 1998-04-07 Shionogi & Co Ltd セフェム系化合物を含有するキマーゼ阻害剤
JPH10101666A (ja) * 1996-10-02 1998-04-21 Shionogi & Co Ltd 新規ベンゾオキサシクロトリデシン化合物およびそれを含有する医薬組成物
KR20000052775A (ko) 1996-10-25 2000-08-25 가마쿠라 아키오 신규한 헤테로사이클릭 아미드 화합물 및 의약으로서의 그의 용도
JPH10245384A (ja) * 1997-03-05 1998-09-14 Teijin Ltd 新規トリアジンスルホン誘導体
EP1055683A4 (de) 1998-02-17 2007-07-25 Nippon Kayaku Kk Neuartiges acetamid-derivat und verwendung desselben
JPH11246437A (ja) * 1998-03-05 1999-09-14 Yoshitomi Pharmaceut Ind Ltd 消化管粘膜保護剤
HUP0103387A3 (en) 1998-08-21 2002-07-29 Daiichi Asubio Pharma Co Ltd Quinazoline derivatives preparation thereof, medicament containing them and their intermediates
JP4491866B2 (ja) * 1999-09-30 2010-06-30 三菱化学株式会社 アシルスルホンアミド誘導体
US6921766B1 (en) 1999-11-01 2005-07-26 Daiichi Suntory Pharma Co., Ltd. Blood vessel lipid deposition-preventive agent comprising chymase-inhibitor
AU3413601A (en) 2000-02-22 2001-09-03 Daiichi Asubio Pharma Co., Ltd. Preventive or therapeutic drugs for dermatitises containing chymase inhibitors as the active ingredient
AU3413401A (en) 2000-02-22 2001-09-03 Daiichi Asubio Pharma Co., Ltd. Preventive or therapeutic drugs for fibrosis containing chymase inhibitors as the active ingredient

Also Published As

Publication number Publication date
US6677344B2 (en) 2004-01-13
EP1174151A4 (de) 2003-01-22
US20020187989A1 (en) 2002-12-12
AU3413501A (en) 2001-09-03
EP1174151A1 (de) 2002-01-23
EP1174151B1 (de) 2007-01-24
CN1245978C (zh) 2006-03-22
WO2001062293A1 (en) 2001-08-30
CA2365606A1 (en) 2001-08-30
DE60126199D1 (de) 2007-03-15
ES2275652T3 (es) 2007-06-16
HUP0201287A3 (en) 2003-02-28
CN1366459A (zh) 2002-08-28
HUP0201287A2 (hu) 2002-12-28
KR20010109526A (ko) 2001-12-10
DE60126199T2 (de) 2008-02-28

Similar Documents

Publication Publication Date Title
ATE485265T1 (de) 5-substituierte-2-phenylaminobenzamide als mek- inhibitoren
ATE375341T1 (de) Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen
MX2008013836A (es) Derivados de 2-piridona para el tratamiento de enfermedades o condiciones en las cuales es benefica la inhibicion de la actividad de elastasa de neutrofilos.
ATE327225T1 (de) Neue verwendung von benzothiazolderivaten
WO2002009702A3 (en) Use of indole derivatives for the manufacture of a medicament for reducing intracular pressure
EP1192949A4 (de) Azneimittel mit chymaseinhibitoren als wirksames mittel, zur vorbeugung oder behandlung von fibrosis
BR0316458A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, método para intensificar a cognição em um paciente saudável, e, uso de um composto
GB0130677D0 (en) Medicaments and novel compounds
ATE366107T1 (de) Verwendung von sulfodehydroabietinsäure zur behandlung entzündlicher darmerkrankungen
EA200601249A1 (ru) Пиперазины, пригодные для лечения боли
DE60126199D1 (de) Therapeutische behandlung von eosinophilie durch verwendung von chymase-inhibitoren als aktiven bestandteilen
ATE550039T1 (de) Mittel zur behandlung von glomerulären erkrankungen
ATE333897T1 (de) Arzneimittel mit chymaseinhibitoren als wirksames mittel zur behandlung von dermatitis mit zweiphasigen hautreaktionen
NZ293691A (en) Use of a medicament containing an anilide compound for treatment of type i allergic diseases
DE69720521D1 (de) Hemmer der subepithelialen turbidität
ATE447953T1 (de) Pharmazeutische zusammensetzungen zur behandlung von leishmaniasis
WO2005035500A3 (en) Therapeutic agents useful for treating pain

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties